These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16979782)

  • 1. Current concepts in RET-related genetics, signaling and therapeutics.
    Plaza-Menacho I; Burzynski GM; de Groot JW; Eggen BJ; Hofstra RM
    Trends Genet; 2006 Nov; 22(11):627-36. PubMed ID: 16979782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
    de Groot JW; Links TP; Plukker JT; Lips CJ; Hofstra RM
    Endocr Rev; 2006 Aug; 27(5):535-60. PubMed ID: 16849421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
    Asai N; Jijiwa M; Enomoto A; Kawai K; Maeda K; Ichiahara M; Murakumo Y; Takahashi M
    Pathol Int; 2006 Apr; 56(4):164-72. PubMed ID: 16634961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene].
    Bendlová B; Dvoráková S; Václavíková E; Sýkorová V; Vlcek P; Skába R
    Vnitr Lek; 2006 Oct; 52(10):926-34. PubMed ID: 17063805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neural crest and multiple endocrinopathies].
    Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
    C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases.
    Runeberg-Roos P; Saarma M
    Ann Med; 2007; 39(8):572-80. PubMed ID: 17934909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease.
    Dvoráková S; Dvoráková K; Malíková M; Skába R; Vlcek P; Bendlová B
    J Pediatr Surg; 2005 Jun; 40(6):e1-6. PubMed ID: 15991157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds.
    Fialkowski EA; DeBenedetti MK; Moley JF; Bachrach B
    J Pediatr Surg; 2008 Jan; 43(1):188-90. PubMed ID: 18206480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients.
    Fernández RM; Navarro E; Antiñolo G; Ruiz-Ferrer M; Borrego S
    Int J Mol Med; 2006 Apr; 17(4):575-81. PubMed ID: 16525712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Y606C RET mutation causes a receptor gain of function.
    Ercolino T; Lombardi A; Becherini L; Piscitelli E; Cantini G; Gaglianò MS; Serio M; Luconi M; Mannelli M
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):253-8. PubMed ID: 18248647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET in human development and oncogenesis.
    Edery P; Eng C; Munnich A; Lyonnet S
    Bioessays; 1997 May; 19(5):389-95. PubMed ID: 9174404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR).
    Fitze G; Appelt H; König IR; Görgens H; Stein U; Walther W; Gossen M; Schreiber M; Ziegler A; Roesner D; Schackert HK
    Hum Mol Genet; 2003 Dec; 12(24):3207-14. PubMed ID: 14600022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEN2 screening dilemmas in a family with a novel RET mutation in the MEN2 susceptibility region of the gene, a family history of Hirschsprung disease, and no family history of MEN2-related tumours.
    Clowes VE; Shaw-Smith C; Simpson H; Ball SG; Acerini CL
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):666-7. PubMed ID: 17877758
    [No Abstract]   [Full Text] [Related]  

  • 14. A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2.
    Vanhorne JB; Andrew SD; Harrison KJ; Taylor SA; Thomas B; McDonald TJ; Ainsworth PJ; Mulligan LM
    Oncogene; 2005 Feb; 24(6):1091-7. PubMed ID: 15592530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes.
    Fernández RM; Antiñolo G; Eng C; Borrego S
    Hum Mutat; 2003 Nov; 22(5):412-5. PubMed ID: 14517954
    [No Abstract]   [Full Text] [Related]  

  • 17. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.
    Joshi PP; Kulkarni MV; Yu BK; Smith KR; Norton DL; van Veelen W; Höppener JW; Franklin DS
    Oncogene; 2007 Jan; 26(4):554-70. PubMed ID: 16953232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.
    Mise N; Drosten M; Racek T; Tannapfel A; Pützer BM
    Oncogene; 2006 Oct; 25(50):6637-47. PubMed ID: 16715139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.
    Castellone MD; Verrienti A; Magendra Rao D; Sponziello M; Fabbro D; Muthu M; Durante C; Maranghi M; Damante G; Pizzolitto S; Costante G; Russo D; Santoro M; Filetti S
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):529-34. PubMed ID: 20039896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.